Raven Aravind
Acute Care · Dallas, TXNPI 1518592534
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,222 of the $1,600 with a category attached, or 76.4%. It is spread thinly across 29 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,096 and has fallen 97.7% since, to $25 in 2024.
Across 69 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$332
- Johnson & Johnson$157
- Pfizer$89
- Amgen$85
- Astellas Pharma US Inc$81
- Novartis$80
- plus $777 from 23 others
What the payments were for
- Food & beverage$1,22276%
- Education$37824%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 7 | $332 |
| Johnson & Johnson | 5 | $157 |
| Pfizer | 5 | $89 |
| Amgen | 4 | $85 |
| Astellas Pharma US Inc | 4 | $81 |
| Novartis | 4 | $80 |
| AstraZeneca | 4 | $73 |
| Ipsen Biopharmaceuticals, Inc | 2 | $53 |
| Eisai Inc. | 2 | $47 |
| Sobi, Inc | 3 | $46 |
| GSK | 2 | $46 |
| Merck | 2 | $46 |
| Foundation Medicine, Inc. | 2 | $42 |
| Puma Biotechnology, Inc. | 2 | $39 |
| Agios Pharmaceuticals, Inc. | 2 | $38 |
| Sanofi | 2 | $38 |
| Morphosys, US Inc. | 2 | $36 |
| Gilead | 2 | $34 |
| Rigel Pharmaceuticals, Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Boston Scientific | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Dova Pharmaceuticals | 2 | $23 |
| Bristol Myers Squibb | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Array Biopharma Inc | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $17 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $16 |
How this compares
$1,600 in reported general payments places this provider in the 80th percentile of 2,323 acute care providers in Texas.
Other acute care in Dallas
- Jennifer PilotteDallas$232K
- Amanda BradleyDallas$85K
- Martha LibertyDallas$28K
- Rachael SchneiderDallas$20K
- Peter TriporoDallas$15K
- Mario PadillaDallas$13K
- Toni SmithDallas$10K
- Christie MorrisonSan Antonio$225K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.